evidence table
Sodium Potassium Blood Pressure Guideline Evidence Table
Structured evidence table for Sodium Potassium Blood Pressure Guideline, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sodium Potassium Blood Pressure Guideline | Recognizing these signals as expected manifestations of effective therapy, rather than harmful events, allows clinicians to maintain evidence-based drugs at target or near-target doses and to fully realize the mortality reduction associated with comprehensive guideline-directed medical therapy (GDMT). | 2 | Bellicini MG (2026) | Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry. |
| Sodium Potassium Blood Pressure Guideline | A paradox persists in contemporary heart failure (HF) care, whereby the therapies most clearly proven to save the most lives are also those most frequently interrupted, often for reasons that are more physiological than pathological. | 2 | Bellicini MG (2026) | Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry. |
| Sodium Potassium Blood Pressure Guideline | Indeed, during HF medical therapy bradycardia, modest increases in creatinine or potassium levels, mild reductions in blood pressure, and concern regarding hypoglycemia are frequently perceived as dangerous adverse effects of drugs therapy, leading to premature dose reductions or discontinuation. | 2 | Bellicini MG (2026) | Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry. |
| Sodium Potassium Blood Pressure Guideline | Even mild elevations in serum potassium are associated with increased risks of arrhythmia, hospitalization, and mortality, underscoring the importance of effective potassium management. | 3 | Jung Jinah (2026) | Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate |
| Sodium Potassium Blood Pressure Guideline | 2 3 4 Beyond its direct clinical risks, hyperkalemia represents a major barrier to the optimal implementation of guideline-directed medical therapy for cardiorenal disease. | 3 | Jung Jinah (2026) | Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate |
| Sodium Potassium Blood Pressure Guideline | Observational studies consistently demonstrate that RAASi discontinuation following hyperkalemia is associated with worse cardiovascular and renal outcomes, highlighting the clinical importance of maintaining potassium homeostasis while preserving life-saving pharmacotherapy []. | 3 | Jung Jinah (2026) | Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate |
| Sodium Potassium Blood Pressure Guideline | 1 Hyperkalemia is a frequent and clinically significant complication in patients with chronic kidney disease (CKD), heart failure (HF), and diabetes mellitus. | 3 | Jung Jinah (2026) | Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate |
Source documents